Amgen has inaugurated its new drug substance facility in the US after announcing a $1bn further expansion at the North Carolina (NC) site to address increasing demand for its medicines.
A ground-breaking ceremony was conducted for this new expansion in Holly Springs.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The total investment of $1.5bn underscores the significance of domestic manufacturing, particularly in the life sciences hub of North Carolina’s Research Triangle.
The two drug substance facilities will exceed 500,000ft².
Leveraging single-use technology, the new Amgen NC facility will incorporate traditional stainless steel-fed batch plant processes.
This approach has a reduced physical footprint and uses 50% less water than conventional plants, aiding the company’s ambition to reach carbon neutrality by 2027.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSituated in the Research Triangle’s core, the Holly Springs site at Camp Helix Innovation Park signifies a substantial regional investment.
Amgen CEO Bob Bradway stated: “We chose Holly Springs because the Research Triangle area offers unbeatable advantages, including a welcoming investment climate, a thriving innovation ecosystem and a diverse and skilled workforce.
“This plant will further strengthen our ability to provide an uninterrupted supply of our medicines for patients suffering from heart disease, cancer and other serious illnesses.”
The initial plant will employ 350 full-time staff. Further expansion will increase this to 700 jobs by 2030.
Roles will include engineers, quality professionals and manufacturing associates.
Almost 70% of the site’s employees are North Carolina residents.
The new facilities are poised to utilise the company’s technological and operational expertise for the timely distribution of life-saving medicines globally.
The company previously received US Food and Drug Administration (FDA) approval for its LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination therapy for treating adults with KRAS G12C-mutated metastatic colorectal cancer.
